Tempest Therapeutics, Inc. (TPST) Stock Price & Analysis
Tempest Therapeutics, Inc. (TPST) fell 1.56% to USD 0.93 as of July 25, 2026 at 10:39 UTC, according to Nexqual real-time market data.
TPST last closed at USD 0.94; the session ranged USD 0.87–0.99 on volume of 250,865 shares. Market capitalization is $14.80M, with a 52-week range of USD 0.87–12.23 (NCM). Source: Nexqual, July 25, 2026 at 10:39 UTC.
Key Statistics (as of July 25, 2026 at 10:39 UTC)
| Price | USD 0.93 |
|---|---|
| Change | ▼ 1.56% (down) |
| Previous Close | USD 0.94 |
| Open | USD 0.93 |
| Day Range | USD 0.87 – 0.99 |
| 52-Week Range | USD 0.87 – 12.23 |
| Volume | 250,865 shares |
| Market Cap | $14.80M |
| Exchange | NCM |
Technical Analysis (TPST)
Nexqual's technical model rates TPST "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 10:39 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 31.03 (neutral) |
| vs SMA50 | Below (USD 1.29) |
| MACD | -0.09 (negative) |
Analyst Ratings (TPST)
Wall Street analysts rate TPST "None" based on 1 analysts, with a mean price target of USD 11 (range USD 11–11), per Nexqual as of July 25, 2026 at 10:39 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 11 |
| High Target | USD 11 |
| Low Target | USD 11 |
Earnings (TPST)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.3 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.5 vs est -0.28 ▼ miss |
| 2025-12-31 | USD -0.62 vs est -0.62 ▲ beat |
| 2025-09-30 | USD -0.79 vs est -3.27 ▲ beat |
| 2025-06-30 | USD -2.07 vs est -3.23 ▲ beat |
Source: Nexqual, July 25, 2026 at 10:39 UTC.
Financials & Fundamentals (TPST)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -721.00% |
| Debt / Equity | 955.47 |
| Current Ratio | 0.74 |
| Total Cash | $1.80M |
| Total Debt | $7.85M |
| Free Cash Flow | $-16.63M |
Source: Nexqual, July 25, 2026 at 10:39 UTC.
Financial Health Score (TPST)
Nexqual rates Tempest Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 10:39 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Critical — $2M cash vs $8M debt |
| Cash Flow | Weak — Operating cash flow -$26M |
| Efficiency | Critical — ROE -721%, ROA -61.7% |
Ownership (TPST)
| Insider Ownership | +31.78% |
|---|---|
| Institutional Ownership | +26.29% |
| Shares Outstanding | 15.98M |
| Float | 9.73M |
| Short % of Float | +4.25% |
Source: Nexqual, July 25, 2026 at 10:39 UTC.
Leadership (TPST)
Tempest Therapeutics, Inc. is led by Matthew Angel (age 44), President, CEO & Director, per Nexqual as of July 25, 2026 at 10:39 UTC.
| President, CEO & Director | Matthew Angel (age 44) |
|---|
Major Backers & Investors (TPST)
Notable institutional backers of Tempest Therapeutics, Inc. include Versant Venture Management, LLC, Fidelity, FMR, LLC, according to Nexqual as of July 25, 2026 at 10:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Versant Venture Management, LLC | 1.69% |
| Fidelity | 0.47% |
| FMR, LLC | 0.21% |
| Sabby Management, LLC | 0.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.36% |
| Geode Capital | 0.54% |
| BlackRock | 0.24% |
Source: Nexqual, July 25, 2026 at 10:39 UTC.
From Tempest Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- We expect this strategy to allow us to pursue parallel development of multiple programs while managing internal cash resources and extending our operational runway.   Our Pipeline Our product development pipeline consists of the following product candidates:   1. "RCC" renal cancer; "CCA" cholangiocarcinoma; "FPI" First Patient In; "SLE" lupus.
Partnerships
- On February 3, 2026, the Restated Factor Services Agreement was assigned to us in connection with the Closing pursuant to the Asset Purchase Agreement.
- Roche Collaboration Agreement In February 2021, we entered into a collaboration agreement with F.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RNAZ | TransCode Therapeutics, Inc. | USD 5.93 | ▼ 29.4% |
| AVTX | Avalo Therapeutics, Inc. | USD 18.44 | ▲ 1.6% |
| CDIO | Cardio Diagnostics Holdings Inc | USD 1.55 | ▼ 7.74% |
| ABVC | ABVC Biopharma, Inc. | USD 1.15 | ▼ 2.54% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.26 | ▼ 7.96% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 10:39 UTC. This page is informational and not investment advice.